A Pilot Study to Evaluate the Safety of Terbutaline in Children With Type 1 Diabetes
Completed
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 1
2008-02-01
The purpose of the study is to gain experience with the use of terbutaline in children with
T1D and to determine that there is not a frequent serious, unexpected, uncontrollable effect
on short-term glycemic control. Some information also will be obtained with regard to whether
terbutaline, in the dosing being used in the study, is sufficiently well tolerated to expect
that adherence will be satisfactory in a large randomized trial. In addition, this pilot
study will provide data on the accuracy of a continuous glucose monitor during terbutaline
use to verify that the drug does not impact on sensor function.
A Pilot Study to Evaluate the Safety of Terbutaline in Children With Type 1 Diabetes
Completed
Jaeb Center for Health Research
Phase 1
2008-02-01
The purpose of the study is to gain experience with the use of terbutaline in children with
T1D and to determine that there is not a frequent serious, unexpected, uncontrollable effect
on short-term glycemic control. Some information also will be obtained with regard to whether
terbutaline, in the dosing being used in the study, is sufficiently well tolerated to expect
that adherence will be satisfactory in a large randomized trial. In addition, this pilot
study will provide data on the accuracy of a continuous glucose monitor during terbutaline
use to verify that the drug does not impact on sensor function.
Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline
Terminated
Yaakov Beilin
Phase 2/Phase 3
2014-07-01
Breech presentation of a term pregnancy is a common occurrence. A procedure known as external
cephalic version (ECV) is frequently used by obstetricians to turn the baby into the vertex
position prior to delivery in order to avoid a cesarean section and the associated risks.
Medications to relax the uterus, known as tocolytics, are used in conjunction with the
procedure as they have been shown to improve the success rate of ECV, but with inconsistent,
varying results.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
